Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders?

PR Newswire


Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.


The proposed transactions may contain terms that could limit superior competing offers.


Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

NEW YORK

,

May 12, 2026

/PRNewswire/ — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:


Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)’s
 sale to Angelini Pharma S.p.A. for $31.50 per share in cash. If you are a Catalyst shareholder, click here to learn more about your rights and options.


UniFirst Corporation (NYSE: UNF)’s
sale to Cintas Corporation for $155.00 in cash and 0.7720 shares of Cintas stock for each UniFirst share. If you are a UniFirst shareholder, click here to learn more about your rights and options.  


RE/MAX Holdings, Inc. (NYSE: RMAX)’s
 sale to The Real Brokerage Inc. for either 5.152 shares of the combined company or $13.80 in cash per share. If you are a RE/MAX shareholder, click here to learn more about your rights and options.


ACRES Commercial Realty Corp. (NYSE: ACR)’s
merger with ACRES Capital Corp. If you are an ACRES Commercial shareholder, click here to learn more about your legal rights and options.

On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/are-cprx-unf-rmax-acr-obtaining-fair-deals-for-their-shareholders-302768947.html

SOURCE Halper Sadeh LLP

Are KW, BRNS, AFBI Obtaining Fair Deals for their Shareholders?

PR Newswire


Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.


The proposed transactions may contain terms that could limit superior competing offers.


Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

NEW YORK, May 12, 2026 /PRNewswire/ — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:


Kennedy-Wilson Holdings, Inc. (NYSE: KW)’s
 sale to consortium led by William McMorrow, Chairman and Chief Executive Officer of Kennedy-Wilson, and certain other senior executives of Kennedy-Wilson, together with Fairfax Financial Holdings Limited, for $10.90 per share in cash. If you are a Kennedy-Wilson shareholder, click here to learn more about your rights and options.


Barinthus Biotherapeutics plc (NASDAQ: BRNS)’s
 merger with Clywedog Therapeutics, Inc. Under the terms of the agreement, Barinthus shareholders will receive one share of common stock in the new combined company for each American Depositary Share or ordinary share owned. If you are a Barinthus shareholder, click here to learn more about your rights and options.


Affinity Bancshares, Inc. (NASDAQ: AFBI)’s
sale to Fidelity BancShares (N.C.), Inc. for $23.00 per share in cash, subject to adjustment based on Affinity’s adjusted stockholders’ equity at closing. If you are an Affinity shareholder, click here to learn more about your legal rights and options.

On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/are-kw-brns-afbi-obtaining-fair-deals-for-their-shareholders-302768944.html

SOURCE Halper Sadeh LLP

Are CNTA, WSR, GDOT Obtaining Fair Deals for their Shareholders?

PR Newswire


Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.


The proposed transactions may contain terms that could limit superior competing offers.


Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

NEW YORK, May 12, 2026 /PRNewswire/ — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:


Centessa Pharmaceuticals plc (NASDAQ: CNTA)’s
sale to Eli Lilly and Company for $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. If you are a Centessa shareholder, click here to learn more about your legal rights and options.


Whitestone REIT (NYSE: WSR)’s
sale to Ares Management Corporation for $19.00 per share or unit. If you are a Whitestone shareholder, click here to learn more about your legal rights and options.


Green Dot Corporation (NYSE: GDOT)’s
sale to Smith Ventures and CommerceOne Financial Corporation for $8.11 in cash and 0.2215 shares of a new publicly traded bank holding company for each share of Green Dot. If you are a Green Dot shareholder, click here to learn more about your rights and options.

On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/are-cnta-wsr-gdot-obtaining-fair-deals-for-their-shareholders-302768946.html

SOURCE Halper Sadeh LLP

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart Failure Therapies –

− Pooled Analysis of Over 25,000 Patient-Years of Experience with TTR-Silencing RNAi Therapies Shows a Consistent Safety Profile, Including No Clinically Meaningful Ocular Effects of Vitamin A Lowering –

− DemonsTTRate Study Designed to Generate Long-Term Real-World Evidence in More Than 2,000 Patients with ATTR-CM −

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), adding to the growing body of evidence supporting vutrisiran and reinforcing the durability of transthyretin (TTR) knockdown and its well-characterized safety profile. Vutrisiran is the first and only TTR silencer approved for ATTR-CM that is designed to deliver rapid knockdown of TTR at the source. The data presented at Heart Failure 2026, the annual congress of the Heart Failure Association of the European Society of Cardiology, show consistent clinical benefit across patient populations commonly encountered in clinical practice, including those with a high disease burden, supporting its use as a first-line treatment option for this rapidly progressive and life-threatening disease.

“The analyses presented at Heart Failure 2026 provide important insights into how vutrisiran performs across the patients we see in clinical practice, including those who present with features such as atrial fibrillation, low systolic blood pressure and a high comorbidity burden,” said Scott Solomon, M.D., Professor of Medicine at Harvard Medical School and cardiologist at Brigham and Women’s Hospital. “These new HELIOS-B analyses show that the clinical benefits of vutrisiran were maintained across these clinically complex patient groups, as well as in patients receiving background therapies, including TTR stabilizers and disease-modifying heart failure therapies, reinforcing both the consistency of the treatment effect and its relevance in real-world clinical practice. Taken together, these findings support the use of vutrisiran as a first-line treatment option for ATTR-CM across a broad range of patient populations.”

In patients with atrial fibrillation, representing approximately 65% of the HELIOS-B study population and associated with more advanced disease, vutrisiran significantly reduced the risk of all-cause mortality and recurrent cardiovascular (CV) events compared with placebo. Treatment effects were also maintained in patients with low systolic blood pressure (SBP), a higher-risk phenotype, with vutrisiran slowing the progressive decline in SBP observed over time. Clinical benefits were similarly consistent regardless of comorbidity burden or concomitant use of disease-modifying therapies, including tafamidis and heart failure medications such as SGLT2 inhibitors, MRAs, ß-blockers and ACEi/ARB/ARNI. Consistent effects were also observed in women, a historically underrepresented population in ATTR-CM trials.

A separate pooled analysis of clinical trial and post-marketing safety data evaluated the relationship between transthyretin-lowering RNAi therapies and vitamin A deficiency-related adverse events. Patients treated with vutrisiran and patisiran are suggested to take the recommended daily allowance of vitamin A. The analysis included more than 25,000 patient-years of treatment exposure across vutrisiran and patisiran programs. Rates of ocular adverse events potentially associated with vitamin A deficiency were low and comparable to placebo. No cases of clinically meaningful vitamin A deficiency were observed.

“Vitamin A plays an essential role in vision and other key physiological functions. While transthyretin contributes to its transport, multiple pathways support its delivery throughout the body,” said William S. Blaner, Ph.D., Professor of Nutritional Medicine at Columbia University and expert in vitamin A metabolism and transport. “The low and comparable to placebo rates of vitamin A deficiency-related adverse events observed in this large analysis provide strong reassurance that lowering transthyretin does not meaningfully increase these events in patients with ATTR amyloidosis.”

Alnylam also presented the design and rationale of the DemonsTTRate study, a global, prospective, observational study evaluating real-world outcomes in patients with ATTR-CM. The study is expected to enroll more than 2,000 patients and follow them for up to five years, generating longitudinal data on clinical outcomes, treatment patterns and healthcare utilization across routine clinical practice.

Across ATTR-CM and hereditary transthyretin-mediated amyloidosis with polyneuropathy (hATTR-PN), worldwide experience with vutrisiran to date exceeds 13,000 patient-years, reflecting a robust and expanding body of clinical evidence across both manifestations of the disease. To view Alnylam’s Heart Failure 2026 presentations please visit Capella.

AMVUTTRA® (vutrisiran) INDICATIONS AND IMPORTANT SAFETY INFORMATION

Indications

In the EU, AMVUTTRA® (vutrisiran) is indicated for the treatment of:

  • hereditary transthyretin amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy (hATTR-PN).

  • wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).

Availability across the EU is subject to local reimbursement timelines.

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

Vutrisiran treatment leads to a decrease in serum vitamin A levels. Supplementation of approximately, but not exceeding, 2500 IU to 3000 IU vitamin A per day is advised for patients taking vutrisiran. Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

Commonly reported adverse reactions with vutrisiran were injection site reactions and increase in blood alkaline phosphatase and alanine transaminase.

For additional information about vutrisiran, please see the full Summary of Product Characteristics.

About AMVUTTRA® (vutrisiran)

AMVUTTRA® (vutrisiran) is a transthyretin (TTR) silencer that delivers rapid knockdown of TTR at the source to address the underlying cause of transthyretin amyloidosis (ATTR). In a clinical study, AMVUTTRA rapidly knocked down TTR in as early as six weeks and decreased TTR levels by 87% with two and a half years of treatment. It isapproved as a treatment for the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults and for the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults in various countries, globally. Administered quarterly via subcutaneous injection, AMVUTTRA is the first and only silencer approved for the treatment of ATTR-CM and hATTR-PN.

About Transthyretin Amyloidosis (ATTR)

Transthyretin amyloidosis (ATTR) is an underdiagnosed, rapidly progressive, debilitating, and fatal disease caused by pathogenic transthyretin (TTR) proteins, which accumulate as amyloid deposits in various parts of the body, including the nerves, heart, and gastrointestinal tract. Patients may present with polyneuropathy, cardiomyopathy, or both manifestations of disease. There are two different forms of ATTR – hereditary ATTR (hATTR), which is caused by a TTR gene variant, and wild-type ATTR (wtATTR), which occurs without a TTR gene variant. It is estimated that more than 500,000 people worldwide live with ATTR.

About RNAi

RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health.

Alnylam Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam’s expectations, beliefs, goals, plans or prospects, including, without limitation, statements regarding the potential for vutrisiran to be used as a first-line treatment for ATTR-CM; the potential efficacy of vutrisiran in patients who present with features such as atrial fibrillation, low systolic blood pressure and a high comorbidity burden; the number of patients who will be enrolled in the DemonsTTRate study, the duration of the follow-up period for those patients, and the data the study will generate; and Alnylam’s ability to execute on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health, should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam’s ability to successfully execute on its “Alnylam 2030” strategy; Alnylam’s ability to successfully launch, market and sell Alnylam’s approved products globally, including AMVUTTRA; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam’s product candidates; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; delays, interruptions or failures in the manufacture and supply of Alnylam’s marketed products or its product candidates; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations; Alnylam’s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products; the outcome of litigation and government investigations; the risk of future litigation and government investigations; and unexpected expenditures; as well as those risks and uncertainties more fully discussed in the “Risk Factors” filed with Alnylam’s 2025 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam’s subsequent Quarterly Reports on Form 10-Q, and in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

Alnylam Pharmaceuticals, Inc.

Christine Akinc

(Investors and Media)

+1-617-682-4340

Josh Brodsky

(Investors)

+1-617-551-8276

KEYWORDS: Massachusetts Europe United States North America

INDUSTRY KEYWORDS: Health Genetics Clinical Trials Pharmaceutical Cardiology Biotechnology

MEDIA:

Logo
Logo

QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting

QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting

  • Co-founder and former CEO Dr. Metin Colpan to become Honorary Chairman of the Supervisory Board after deciding not to stand for re-election
  • Robert McMahon nominated for election to Supervisory Board as part of ongoing renewal process, with seven of eight proposed members having joined since 2021
  • 40% increase in annual dividend proposed to $0.35 per share, reflecting continued commitment to increasing returns to shareholders
  • Additional share repurchase authorizations, including authorization for further open-market share repurchases and a new $200 million synthetic share repurchase
  • Thierry Bernard to stand for re-election as Managing Board member until a new CEO has been appointed; Roland Sackers to stand for re-election to Managing Board

VENLO, Netherlands–(BUSINESS WIRE)–
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced proposals for its 2026 Annual General Meeting, including plans to appoint co-founder and former Chief Executive Officer Dr. Metin Colpan as Honorary Chairman, the continued renewal of the Supervisory Board and increased returns to shareholders.

The Annual General Meeting, to be held on June 24, 2026, in Venlo, the Netherlands, will include proposals to elect Robert McMahon as a new member of the Supervisory Board, approve a 40% increase in the annual cash dividend and authorize additional shareholder returns through a synthetic share repurchase of up to the currently allowed maximum of $200 million as well as further open-market share repurchases.

These proposals come as QIAGEN continues a significant renewal of its Supervisory Board. Following the Annual General Meeting, seven of the eight proposed Supervisory Board members will have joined since 2021, while maintaining continuity and institutional knowledge through longer-tenured members and experienced Board and committee leadership.

Following the Annual General Meeting, the Supervisory Board would continue to be composed of eight members: Stephen H. Rusckowski (Chair), Dr. Toralf Haag, Bert van Meurs, Robert McMahon, Eva van Pelt, Dr. Eva Pisa, Mark P. Stevenson and Elizabeth E. Tallett.

“We are deeply grateful to Metin Colpan for his extraordinary contributions to QIAGEN as co-founder, first Chief Executive Officer and long-serving member of the Supervisory Board,” said Stephen H. Rusckowski, Chair of the Supervisory Board. “These proposals outlined for the Annual General Meeting continue the renewal of our Supervisory Board and reaffirm our commitment to best corporate governance practices, strong Board oversight and long-term value creation for shareholders and other stakeholders.”

Dr. Metin Colpan to be appointed Honorary Chairman of the Supervisory Board

Dr. Colpan has decided to conclude his service on the Supervisory Board at the Annual General Meeting and will not stand for re-election. In recognition of his contributions to QIAGEN, the Supervisory Board intends to appoint him as Honorary Chairman following the meeting.

Dr. Colpan played a defining role in QIAGEN’s creation and development, helping establish its scientific foundation, entrepreneurial culture and long-term strategic direction. A co-founder of QIAGEN, he served as Chief Executive Officer from 1985 to 2003 and helped build the company from a university-linked start-up in Düsseldorf into a global leader in Sample to Insight solutions.

Dr. Colpan’s pioneering scientific work in nucleic acid separation and purification helped shape technologies that became important QIAGEN products, and have since been widely adopted in molecular biology labs across the world. These innovations have enabled faster, more reliable and more efficient isolation and analysis of DNA and RNA, supporting advances across the Life Sciences and clinical diagnostics.

Since 2004, Dr. Colpan has continued to contribute to QIAGEN’s strategic and scientific direction as a member of the Supervisory Board, including as Chair of the Science & Technology Committee since 2014. His contributions have also received external recognition, including his selection as a finalist for the European Patent Office’s 2021 European Inventor Award in the lifetime achievement category. Beyond his scientific and entrepreneurial contributions, Dr. Colpan has been closely associated with QIAGEN’s people-centered culture, emphasizing the importance of translating scientific innovation into lasting impact for customers, patients and society.

“I am deeply grateful to the many QIAGENers whose commitment, expertise and passion have shaped QIAGEN’s development and helped support the genomic revolution,” said Dr. Colpan. “Their work has helped turn scientific ideas into trusted products that support research, diagnostics and better healthcare decisions around the world. It is a privilege to be part of this journey, and I look forward to remaining connected as QIAGEN continues to advance science and improve healthcare.”

Robert McMahon proposed for election to Supervisory Board

Robert McMahon, the Chief Financial Officer of West Pharmaceutical Services, Inc., has been proposed for election to the Supervisory Board.

Prior to this role, he served as Chief Financial Officer of Agilent Technologies Inc. from 2018 to 2025, and as Chief Financial Officer of Hologic, Inc. from 2014 to 2018. Earlier in his career, Mr. McMahon spent 20 years with Johnson & Johnson in executive finance roles of increasing responsibility. He also serves on the Board of Directors of OraSure Technologies, Inc. Mr. McMahon earned a Master of Business Administration from the University of Central Florida and a bachelor’s degree in Finance from the University of Florida.

“We are pleased to propose Robert McMahon for election to QIAGEN’s Supervisory Board,” said Mr. Rusckowski. “He would further strengthen the profile of the Board with deep experience in global healthcare, Life Sciences and public company finance. His financial acumen and track record in the capital markets will be valuable as QIAGEN continues to focus on execution and disciplined capital allocation to the highest return opportunities.”

Proposed annual dividend

QIAGEN is proposing a 40% increase in its annual cash dividend to $0.35 per ordinary share, compared with the initial annual dividend of $0.25 approved by shareholders in 2025.

QIAGEN introduced its first annual dividend in 2025 as an additional way to return capital to shareholders while preserving flexibility to reinvest in long-term growth. The proposed 2026 dividend reflects a disciplined capital allocation approach focused on the highest return opportunities that also includes organic investments, particularly in R&D and commercialization initiatives, as well as targeted M&A opportunities.

The expected dividend timetable for shares listed on both the New York Stock Exchange and Frankfurt Stock Exchange is as follows: ex-date July 7, 2026; record date July 7, 2026; and payment date July 14, 2026.

Additional share repurchase authorizations

QIAGEN is also seeking shareholder approval for additional share repurchase authorizations as part of its disciplined approach to capital allocation and shareholder returns.

These authorizations include authorizations for open-market share repurchases of up to 10% of the Company’s share capital as well as a synthetic share repurchase of up to $200 million. If approved, these authorizations would provide QIAGEN with additional flexibility to return capital to shareholders while continuing to invest in long-term growth opportunities.

Managing Board appointments

Thierry Bernard, Chief Executive Officer, is also proposed for re-election as a Managing Board member until the appointment of a new CEO. The CEO selection process is progressing well, and a successor is currently expected to join during the second half of 2026. In the meantime, Mr. Bernard will continue to lead QIAGEN with the full support of the Supervisory Board to ensure continuity and focus. Roland Sackers, Chief Financial Officer, also stands for re-election as a Managing Board member.

2026 Annual General Meeting information

QIAGEN’s Annual General Meeting will be held on June 24, 2026, at 9:00 a.m. Amsterdam time at Maaspoort, Oude Markt 30, 5911 HH Venlo, the Netherlands. The meeting will also be available via live webcast in listen-only mode. Shareholders will not be able to vote or address the meeting through the webcast and are encouraged to review the materials and vote their shares in advance of the AGM.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Source: QIAGEN N.V.

Category: Corporate

Public Relations

e-mail: [email protected]

Investor Relations

e-mail: [email protected]

KEYWORDS: New York Netherlands North America United States Europe Germany

INDUSTRY KEYWORDS: Research Finance Genetics Clinical Trials Professional Services Other Health Biotechnology General Health Health Science

MEDIA:

Logo
Logo

U.S. Postal Service to Honor Nation’s 250th Anniversary With American Icons Stamps Curated by Ralph Lauren

PR Newswire

A portrait of shared values

NEW YORK, May 12, 2026 /PRNewswire/ — The U.S. Postal Service (USPS) today announced it will honor the nation’s 250th anniversary with the release of American Icons, a collection of 13 commemorative stamps, curated by legendary American designer Ralph Lauren.

The pane celebrates shared national values and the enduring spirit that has defined the American experience for 2 1/2 centuries.

This marks the first time the Postal Service has invited an individual to curate a complete official USPS stamp issuance.

For nearly 60 years, Ralph Lauren has influenced American style with his enduring creative vision that is deeply rooted in the tapestry of American heritage, landscapes, cultures and artistry. A 2025 recipient of the Presidential Medal of Freedom, Lauren is a profound testament to the boundless possibilities of creativity, determination and the American dream. Born in 1939 in the Bronx NY, Mr. Lauren began his remarkable journey by selling his first line of neckties from a single drawer in the Empire State Building and subsequently built one of the most iconic global lifestyle brands in the world. Throughout his life, he has been dedicated to protecting America’s cultural traditions, most notably through his commitment to preserve and conserve the 1813 flag that inspired the nation’s national anthem and became the national symbol — “The Star-Spangled Banner” — for generations to come.

The American Icons stamp collection features 13 photographs selected from Ralph Lauren’s archive and from visuals that have inspired him and that reflect the unique fabric of the nation, representing freedom, independence, equality, opportunity and the pursuit of happiness. The designs include:

  • The American Flag, our standard for freedom, resilience, unity, and bravery.
  • The Baseball Glove, used by Jackie Robinson is an enduring symbol of equality, teamwork, and perseverance.
  • The Pickup Truck, worn and weathered, evokes the honesty of hard work.
  • The Faithful dog, always steadfast in loyalty and trust.
  • The Empire State Building stands tall as a landmark of possibility and ingenuity.
  • The Barn, forever a metaphor for utility, purpose, and community.
  • The Diné (Navajo) Blanket, woven by Naiomi Glasses, celebrates the beauty of traditional artistry.
  • The Teddy Bear represents compassion, kindness, and comfort.
  • The Lighthouse shines as a beacon of guidance, hope, and optimism.
  • The Hamburger, a centerpiece of the American family cookout and the celebrations that unite us.
  • The Racing Sailboat captures the passionate energy of competition.
  • The Horses, running wild, embody the spirit of independence and the freedom we all strive for.

The 12 stamps each include the “American Icons” title and “FOREVER” and “USA” in white text in the upper left or upper right corners. In the center of the stamp pane, surrounded by blue denim and framed by the other 12 stamps, a 13th stamp shows a knit flag designed by Ralph Lauren with text that reads “1776 to 2026.” The text at the top of the selvage reads “American Icons CURATED BY RALPH LAUREN” and the bottom row reads “Celebrating 250 Years of the United States of America.”

The American Icons stamps will be issued in panes of 13. As Forever stamps, they will always be equal in value to the current First-Class Mail 1-ounce price.

The 2026 Mail Use Stamp

Inspired by the artistry of the American Icons collection, the 2026 U.S. Flag Mail Use Stamp will feature a detailed photograph of a knitted interpretation of the U.S. flag taken from Ralph Lauren’s iconic Flag Sweater. One of the most enduring and widely used stamps in the U.S. postal system, it will be available in panes, booklets and coils in a smaller, definitive format for widespread mail use.

News about the stamps is being shared on social media using the hashtag #AmericanIconsStamps. These stamps are available at most Post Offices, usps.com/shopstamps, or by calling 844.737.7826.

A First Look: USPS Stamp Unveiling

The dedication ceremony will take place Tuesday, June 9, at 11 a.m. Eastern at the iconic James A. Farley Post Office Building, 421 Eighth Ave., New York. Elvin Mercado, the Postal Service’s chief retail and delivery officer, will serve as the dedicating official; attendees are encouraged to register at usps.com/americaniconsstamps

“The Postal Service and the United States share a 250-year legacy rooted in binding the nation,” said Sheila Holman, USPS vice president of marketing. “We are honored to have legendary American designer Ralph Lauren curate the American Icons stamps. His remarkable visual archive beautifully captures the aspirational spirit and shared values that have united Americans since before our nation’s founding.”

American Icons Commemorative Capsule Collection

In celebration of the issuance, a commemorative capsule collection will debut on June 9 at select Ralph Lauren retail stores globally, on RalphLauren.com. The capsule includes the 2026 U.S. Flag stamp reimagined as Ralph Lauren’s iconic American Flag Sweater, a classic Polo Shirt and a Ball Cap.

About Ralph Lauren

Ralph Lauren Corporation (NYSE:RL) is a global leader in the design, marketing and distribution of luxury lifestyle products in five categories: apparel, handbags, footwear & accessories, home, fragrances, and hospitality. For nearly 60 years, Ralph Lauren has sought to inspire the dream of a better life through authenticity and timeless style. Its reputation and distinctive image have been developed across a wide range of products, brands, distribution channels and international markets. The Company’s brand names — which include Ralph Lauren, Ralph Lauren Collection, Ralph Lauren Purple Label, Double RL, Polo Ralph Lauren, Lauren Ralph Lauren, Polo Ralph Lauren Children and Chaps, among others — constitute one of the world’s most widely recognized families of consumer brands. For more information, visit https://investor.ralphlauren.com.

Postal Products

Customers may purchase stamps and other philatelic products through The Postal Store at usps.com/shopstamps, by calling 844-737-7826, by mail through USA Philatelic or at Post Office locations nationwide. For officially licensed stamp products, shop the USPS Officially Licensed Collection on Amazon. Additional information on stamps, First Day of Issue Ceremonies and stamp inspired products can be found at StampsForever.com.

Please Note: The United States Postal Service is an independent federal establishment, mandated to be self-financing and to serve every American community through the affordable, reliable and secure delivery of mail and packages to more than 170 million addresses six and often seven days a week. Overseen by a bipartisan Board of Governors, the Postal Service is celebrating its 250th year of service to customers amidst a network modernization plan aimed at restoring long-term financial sustainability, improving service, and maintaining the organization as one of America’s most valued and trusted brands.

The Postal Service generally receives no tax dollars for operating expenses and relies on the sale of postage, products and services to fund its operations.

For USPS media resources, including broadcast-quality video and audio and photo stills, visit the USPS Newsroom. Follow us on X, formerly known as Twitter;Facebook; Instagram; Pinterest; Threads and LinkedIn. Subscribe to the USPS YouTube Channel. For more information about the Postal Service, visit usps.com and facts.usps.com.

National contact: Felicia M. Lott
[email protected]

Ralph Lauren contact: Lindsay Knoll
[email protected]

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/us-postal-service-to-honor-nations-250th-anniversary-with-american-icons-stamps-curated-by-ralph-lauren-302768937.html

SOURCE U.S. Postal Service

Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026

Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026

MARSEILLE, France–(BUSINESS WIRE)–
Regulatory News:

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as of April 16, 2026:

Total number of shares outstanding:

93,934,210

shares

including :

93,921,863

ordinary shares

4,766

Preferred Shares 2016

7,581

Preferred Shares 2017

Total number of theoretical voting rights (1):

93,921,863

 

Total number of exercisable voting rights (2):

93,903,288

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. No voting rights attached to AGAP 2016 and AGAP 2017.

(2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.

Innate Pharma is advancing a portfolio of differentiated potential first and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.

Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

ISIN code

Ticker code

LEI

FR0010331421

Euronext: IPH Nasdaq: IPHA

9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma’s website (www.innate-pharma.com), and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors & Media Relations

Innate Pharma

Stéphanie Cornen

[email protected]

Investor Relations

[email protected]

Media

[email protected]

KEYWORDS: Europe United States North America France

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo
Logo

Tyler Technologies, Inc. Prices Upsized Offering of $1.25 Billion Convertible Senior Notes due 2031

Tyler Technologies, Inc. Prices Upsized Offering of $1.25 Billion Convertible Senior Notes due 2031

  • Opportunistic capital raise with proceeds used to enhance financial flexibility and fund concurrent share repurchases
  • A portion of the proceeds to be used to purchase capped calls intended to offset potential dilution to Tyler’s common stock upon conversion of the Notes

PLANO, Texas–(BUSINESS WIRE)–Tyler Technologies, Inc. (NYSE: TYL) today announced the pricing of its offering of $1,250,000,000 aggregate principal amount of 0.50% convertible senior notes due 2031 (the “Notes”) in a private offering to persons reasonably believed to be “qualified institutional buyers” pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $1,000,000,000 aggregate principal amount of Notes. The issuance and sale of the Notes are scheduled to settle on May 14, 2026, subject to customary closing conditions. Tyler also granted the initial purchasers of the Notes an option to purchase, for settlement within a period of 13 days from, and including, the date the Notes are first issued, up to an additional $187,500,000 aggregate principal amount of Notes.

The Notes will be senior, unsecured obligations of Tyler and will accrue interest at a rate of 0.50% per annum, in each case payable semi-annually in arrears on July 15 and January 15 of each year, beginning on January 15, 2027. The Notes will mature on July 15, 2031 unless earlier repurchased, redeemed or converted. Before April 15, 2031, holders of the Notes will have the right to convert their Notes only upon the occurrence of certain events. From and including April 15, 2031, holders of the Notes may convert their Notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Tyler will settle conversions of the Notes either entirely in cash or in a combination of cash and shares of its common stock, at Tyler’s election. However, upon conversion of any Notes, the conversion value, which will be determined proportionately over a period of multiple trading days, will be paid in cash up to the principal amount of the Notes being converted. The initial conversion rate of the Notes is 2.4634 shares of common stock per $1,000 principal amount of Notes (which represents an initial conversion price of approximately $405.94 per share of common stock). The initial conversion price represents a premium of approximately 30.0% over the last reported sale price of Tyler’s common stock on the New York Stock Exchange of $312.27 per share on May 11, 2026. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.

The Notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Tyler’s option at any time, and from time to time, on or after July 20, 2029, and on or before the 30th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Tyler’s common stock exceeds 130% of the conversion price for a specified period of time and certain other conditions are satisfied. The redemption price will be equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. Holders of the Notes will have the right to require Tyler to repurchase their Notes upon the occurrence of a fundamental change (as defined in the indentures governing the Notes) at a cash repurchase price equal to the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.

Tyler estimates that the net proceeds from the offering will be approximately $1,224.3 million (or approximately $1,408.1 million if the initial purchasers fully exercise their option to purchase additional Notes), after deducting the initial purchasers’ discounts and commissions and estimated offering expenses. Tyler intends to use approximately $162.8 million of the net proceeds to fund the cost of entering into the capped call transactions described below. Tyler expects to use approximately $320.7 million of the net proceeds to repurchase 1,026,900 shares of its common stock concurrently with the offering in privately negotiated transactions effected through one of the initial purchasers of the Notes or its affiliate, as Tyler’s agent, under Tyler’s share repurchase program. Tyler intends to use the remainder of the net proceeds for general corporate purposes. If the initial purchasers exercise their option to purchase additional Notes, then Tyler intends to use a portion of the additional net proceeds to fund the cost of entering into additional capped call transactions as described below. The concurrent repurchases of shares of Tyler’s common stock described above may result in Tyler’s common stock trading at prices that are higher than would be the case in the absence of these repurchases and may have affected the initial terms of the Notes, including the initial conversion price.

In connection with the pricing of the Notes, Tyler entered into privately negotiated capped call transactions with one or more of the initial purchasers or their affiliates or one or more other financial institutions (the “Option Counterparties”). The capped call transactions will cover, subject to anti-dilution adjustments substantially similar to those applicable to the Notes, the number of shares of Tyler’s common stock underlying the Notes. If the initial purchasers exercise their option to purchase additional Notes, then Tyler expects to enter into additional capped call transactions with the Option Counterparties.

The cap price of the capped call transactions will initially be approximately $655.77 per share, which represents a premium of approximately 110% over the last reported sale price of $312.27 per share of Tyler’s common stock on May 11, 2026, and is subject to certain adjustments under the terms of the capped call transactions.

The capped call transactions are expected generally to reduce the potential dilution to Tyler’s common stock upon any conversion of the Notes and/or offset any potential cash payments Tyler is required to make in excess of the principal amount of converted Notes, as the case may be, upon conversion of the Notes. If, however, the market price per share of Tyler’s common stock, as measured under the terms of the capped call transactions, exceeds the cap price of the capped call transactions, there would nevertheless be dilution and/or there would not be an offset of such potential cash payments, in each case, to the extent that such market price exceeds the cap price of the capped call transactions.

In connection with establishing their initial hedges of the capped call transactions, the Option Counterparties or their respective affiliates expect to enter into various derivative transactions with respect to Tyler’s common stock and/or purchase shares of Tyler’s common stock concurrently with or shortly after the pricing of the Notes. This activity could increase (or reduce the size of any decrease in) the market price of Tyler’s common stock or the Notes at that time.

In addition, the Option Counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Tyler’s common stock and/or purchasing or selling Tyler’s common stock or other securities of Tyler in secondary market transactions following the pricing of the Notes and prior to the maturity of the Notes (and are likely to do so (x) following any conversion of the Notes, any repurchase of the Notes by Tyler on any fundamental change repurchase date or any redemption date, (y) following any other repurchase of the Notes if Tyler elects to unwind a corresponding portion of the capped call transactions in connection with such repurchase and (z) if Tyler otherwise elects to unwind all or a portion of the capped call transactions). This activity could also cause or avoid an increase or decrease in the market price of Tyler’s common stock or the Notes, which could affect the ability to convert the Notes, and, to the extent the activity occurs during any observation period related to a conversion of Notes, it could affect the number of shares and value of the consideration that holders of the Notes will receive upon conversion of the Notes.

As described above, Tyler intends to use a portion of the net proceeds of the offering to repurchase shares of its common stock concurrently with the pricing of the offering in privately negotiated transactions. These repurchases, and any other repurchases of shares of Tyler’s common stock, may increase, or reduce the size of a decrease in, the trading price of Tyler’s common stock, and repurchases executed concurrently with the pricing of the offering may have affected the initial terms of the Notes, including the initial conversion price.

The offer and sale of the Notes and any shares of common stock issuable upon conversion of the Notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the Notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the Notes or any shares of common stock issuable upon conversion of the Notes, nor will there be any offer, solicitation or sale of the Notes or any such shares, in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

About Tyler Technologies, Inc.

Tyler Technologies (NYSE: TYL) is a leading provider of technology solutions purpose-built exclusively for the public sector. Tyler’s end-to-end solutions empower local, state, and federal government entities to operate efficiently and transparently with residents and each other. By connecting data and processes across disparate systems, Tyler’s solutions strengthen the core operations of government and help agencies turn insight into action for their communities. With nearly 47,000 successful installations across 15,000 locations, Tyler serves clients in all 50 states, Canada, the Caribbean, Australia, and other international locations. Tyler has been recognized numerous times for growth and innovation, including on Government Technology’s GovTech 100 list.

Forward-Looking Statements

This press release includes forward-looking statements, including statements regarding the completion of the offering and the expected amount and intended use of the net proceeds and the effects of entering into the capped call transactions described above. Forward-looking statements represent Tyler’s current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those indicated in, or implied by, the forward-looking statements. Among those risks and uncertainties are market conditions, the satisfaction of the closing conditions related to the offering and risks relating to Tyler’s business, including those described in periodic reports that Tyler files from time to time with the Securities and Exchange Commission. Tyler may not consummate the offering described in this press release and, if the offering is consummated, cannot provide any assurances regarding its ability to effectively apply the net proceeds as described above. The forward-looking statements included in this press release speak only as of the date of this press release, and Tyler does not undertake to update the statements included in this press release for subsequent developments, except as may be required by law.

#TYL_Financial

Contact: Jennifer Kepler

Tyler Technologies

972.713.3770

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Software Technology Data Management

MEDIA:

Logo
Logo

Elevra Lithium’s Updated NAL Expansion Scoping Study Defines Faster Growth and Lower Costs

BRISBANE, Australia, May 12, 2026 (GLOBE NEWSWIRE) — North American lithium producer Elevra Lithium Limited (“Elevra or Company”) (ASX:ELV; NASDAQ:ELVR) announced today the outcomes of an Updated Scoping Study for expansion of the existing North American Lithium (NAL) mine. Relative to the study from 15 September 20251 this study delivers additional annual concentrate production two years faster than originally planned, similar unit operating costs and unchanged total capital expenditure of US$270 million.

Highlights

  • Process plant design feed rate increased to the permitted average annual 4,
    500 tonnes per day (tpd) in
    Stage 1 and 6,500 tpd in Stage 2; average Life of Mine (LOM) recovery of 71.2%; spodumene concentrate at grade of 5.4% Li

    2

    O.
  • The updated Scoping Study improves the incremental post-tax NPV(8%) of the expansion project from C$479M (US$355M)

    2

    in the previous study

    1

    to C$969M (US$718M)

    2

    or a 102% increase. Approximately 51% of the increase in post-tax NPV is attributable to staging/throughput and other assumption changes while 49% is attributable to the increase in Li

    2

    O price from the previous study.
  • The expansion project provides a total NAL project post-tax NPV(8%) of C$3,112M (US$2,305M)

    2

    , with a post-tax IRR of 41.8% and payback of 25 months.
  • The expanded production rate is increased to 338 thousand tonnes per annum (ktpa) (nominal SC5.4, post ramp up), up from 315 ktpa in the prior scoping study

    1

    .
  • Average LOM C1 unit cost of C$847/t (US$628/t)

    2

    and AISC of C$922/t (US$683/t)

    2

    once the expansion is fully operational similar to the prior study

    1

    .
  • Stage 1 CAPEX of C$96M (US$71M)

    2

    ; Stage 2 CAPEX of C$81M (US$60M)

    2

    ; Stage 3 CAPEX of C$188M (US$139M)

    2

    . Total CAPEX of C$366M, (US$270M)

    2

    .
  • Stage 1 incremental production ramp up will commence in mid-CY27 and Stage 3 construction is forecast to be completed by mid-CY29.
  • The Company’s existing NAL Ore Reserves solely underpin the NAL Expansion production profile with a revised life of mine of 21 years.

The NAL Expansion Project will be delivered based on a development sequence identified by Elevra and published on January 12th, 2026, in the ASX press release “Accelerated NAL Expansion”. The following debottlenecking steps were identified for the delivery of the three Stages:

  • Stage 1: An initial 15-20% increase in annual spodumene concentrate production above current production levels commencing in mid-CY27 with an incremental reduction in unit operating costs. This increase is within the current limits of the milling permit, which is set at 4,500 tpd;
  • Stage 2: A subsequent expansion of downstream milling, flotation and filtration capacity to 6,500 tpd with an anticipated corresponding concentrate production rate of 338 ktpa post expansion. The incremental feed material will be processed using a temporary mobile crushing circuit operating in conjunction with the existing crushing circuit. The further expanded production is expected to commence early CY28, with an additional incremental reduction in unit operating costs; and
  • Stage 3: The replacement of the temporary mobile crushing circuit and the existing crushing circuit with a new crushing circuit capable of meeting feed requirements for a LOM average production of 338ktpa. This final step will include additional ore sorting capacity and is expected to be completed in early CY29 delivering crushing cost efficiencies which are required to meet the anticipated LOM cost reduction.

Elevra’s Chief Executive Officer and Managing Director, Mr Lucas Dow, said: “The updated Scoping Study demonstrates the significant value uplift achievable through a staged expansion of the North American Lithium mine. Adopting this staged development approach allows Elevra to bring additional production forward on an accelerated timeline compared with the previously contemplated whole-of-project expansion. Additionally, we see the staged development as a disciplined and practical pathway to growth, allowing us to deliver measurable progress through clearly defined milestones rather than relying on a single step-change outcome. By advancing the project in phases, we can progressively increase production capacity, optimise operating performance, reduce costs and incorporate learnings at each stage of development.

“This approach strengthens execution certainty, supports prudent capital deployment and enables the team to achieve tangible operational and financial objectives along the way, while maintaining flexibility to respond to market conditions. Ultimately, the staged model enables Elevra to build scale responsibly, generate cashflow earlier, improve capital efficiency, and deliver a reduction in unit operating costs to enhance returns and project economics.

“As global lithium demand continues to grow, the Updated Scoping Study, combined with the technical and operational knowledge gained on site, reinforces our confidence in NAL’s expansion pathway and highlights a clear opportunity to deliver sustainable long-term value.”

Updated Scoping Study Metrics

Analysis of the financial model on the key economic assumptions indicates that the Project is robust in terms of operational and financial metrics. The Project is most sensitive to changes in commodity prices, exchange rates, head grades and recoveries, with the key Project assumptions and outputs shown in the tables below (please note that any reference to Base Case means NAL on an unexpanded or “as is” basis):


Table 1 – Main Financial Assumptions and Results Summary for the NAL Expansion Project

Parameters Unit   Base
  Expansion
 
Average Price 6% Li2O3 USD$/t   $2,261   $2,154  
Life of mine (from 2025) yrs   35   21  
Total Waste Mt   335   335  
Total Ore Mt   47   47  
Strip Ratio   7.2   7.2  
Average Annual ROM Mt/y   1.3   2.4  
Average Feed Grade % Li2O   1.11%   1.11%  
LOM 5.4% Li2O Produced Mt   6.72   6.85  
Average Annual 5.4% Li2O production (post
expansion – Life of Mine (LOM))
kt/y   194   338  
 


Table 2 – Project Economics

Project Economics Unit   Base   Expansion  
LOM C1 Cost Concentrate C$/t conc   1,076   868  
LOM AISC C$/t conc   1,152   946  
LOM C1 Cost of Concentrate (post expansion) C$/t conc   1,071   847  
LOM AISC (post expansion) C$/t conc   1,146   922  
Total Sustaining Capital (SUSEX) C$M   506   526  
Total Initial CAPEX C$M     366  
NPV (8%) (post-tax) C$M   2,143   3,112  
IRR Expansion (post-tax) %     42%  
Payback (post-tax) Months     25  
             

Notes:

  • All costs and sales are presented in constant 2026 CAD, with no inflation or escalation factors considered.
  • $M = millions of dollars.
  • The financial analysis was performed on existing Ore Reserves as outlined in this report.
  • The valuation calculations are unlevered.
  • The average metallurgical recovery over the LOM is 71.2% for the expansion and 69.2% for the base case due to improvement in the mill flowsheet specifically attributable to wet high-intensity magnetic separator (WHIMS) improvements.
  • Plant availability is calculated at 90%.
  • Tonnes of concentrate are presented as dry metric tonnes.
  • An exchange rate of 0.74 CAD/USD was fixed over the LOM for the Project.
  • The average 6% Li2O concentrate (SC6) price is based on a market analysis from Benchmark Mineral Intelligence for Q1 2026 as described in the market section and varies over the LOM from US$1,260/t to US$2,430/t.
  • Average LOM SC6 pricing may vary between the cases due to longer mine life at the long term US$2,430 price for the base case (2036 and beyond).
  • A discount rate of 8% was used for the base case and expansion scenarios.
  • Net Cash Flow and valuation calculations include investment tax credit on CAPEX.
  • The numbers have been rounded. Any discrepancy in the totals is due to rounding effects.

Cautionary Statements

The Updated Scoping Study discussed herein has been undertaken to determine the feasibility of a brownfield expansion of the existing NAL operation. The Updated Scoping Study is a preliminary technical and economic study of the feasibility of an expansion development of the NAL Operation. The Updated Scoping Study is based on low-level technical and economic assessments and is insufficient to provide assurance of an economic development case at this stage.

The Updated Scoping Study evaluation work and appropriate studies have provided Updated Scoping level estimates of cost and rates of return. The production target underpinning financial forecasts included in the Updated Scoping Study are based solely upon current Ore Reserves estimated in the Announcement (See Sayona ASX announcement dated 27 August 2025).

The Updated Scoping Study is based on the material assumptions outlined elsewhere in this announcement. These include assumptions about the availability of funding. There is no certainty that the Project will be able to be funded when needed (nor any certainty as to the form such funding may take, such as disclosed in this announcement). It is also possible that such funding may only be available on terms that dilute or otherwise affect the value of the Company’s shares. While Elevra considers all of the material assumptions to be based on reasonable grounds, there is no certainty that they will prove to be correct or that the range of outcomes indicated by the Updated Scoping Study will be achieved. This announcement contains forward‐looking statements. Elevra has concluded it has a reasonable basis for providing the forward‐looking statements included in this announcement. However, a number of factors could cause actual results, or expectations to differ materially from the results expressed or implied in the forward-looking statements. Given the uncertainties involved, investors should not make any investment decisions based solely on the results of the Updated Scoping Study and are cautioned not to place undue reliance on the Updated Scoping Study or the production targets referred to in this announcement.

Overview

The North American Lithium operation is a hard-rock lithium mining and concentration facility located in La Corne, within the Abitibi-Témiscamingue region of Quebec, Canada. The NAL facility was successfully restarted in March 2023, and the plant is currently permitted for 4,500 tpd of average annual milling rate.

The processing operation consists of three distinct processing areas:

  • The primary, secondary and tertiary crushing, and ore sorting circuits to produce an upgraded plant feed for downstream processing.
  • The spodumene processing plant including grinding, desliming, magnetic separation, flotation and dewatering circuits to produce a final spodumene concentrate.
  • The process water and utilities circuits including tailings thickeners, reagents preparation, reverse osmosis treatment, and tailings management.

The objective of the NAL expansion project is to increase the plant’s milling throughput to an annual level of 6,500 tpd. Elevra determined that permitting is the critical path constraint and identified a project development sequence that provides a shorter timeframe to achieve increased production from NAL. The additional new permitting information, combined with existing permits, provides a pathway to stage the expansion of production volumes at NAL in a disciplined, agile and more time efficient manner.

The expansion pathway is now proposed to take the form of a series of debottlenecking steps which are expected to:

  • Increase production capacity above current levels in a staged and incremental manner;
  • Improve plant recovery by the introduction of additional LIMS and WHIMS, and additional flotation conditioning capacity;
  • Reduce the timeframe to achieve the expanded average Life of Mine (LOM) production volume of 338ktpa of spodumene concentrate; and
  • Enable the capital investment to be staged and, in doing so, reduce the initial upfront capital requirements.

The debottlenecking steps are anticipated to be delivered as below:

  1. An initial 15-20% increase in annual spodumene concentrate production above current production levels commencing in mid-CY27 with an incremental reduction in unit operating costs. This increase is within the current limits of the milling permit, which is set at 4,500 tpd;
  2. A subsequent expansion of the milling, flotation and filtration capacity to 6,500 tpd with an anticipated corresponding concentrate production rate of 338 ktpa post expansion. The incremental feed material will be processed using a temporary mobile crushing circuit operating in conjunction with the existing crushing circuit. The further expanded production is expected to commence early CY28, with an additional incremental reduction in unit operating costs; and
  3. The replacement of the temporary mobile crushing circuit and the existing crushing circuit with a new crushing circuit capable of meeting feed requirements for a LOM average production of 338 ktpa post expansion. This final step is expected to be completed in mid-CY29 and is expected to deliver crushing cost efficiencies required to meet the anticipated LOM cost reduction.

Property Status

The NAL Expansion Project properties (the “Properties”) are situated in the La Corne Township in the Abitibi-Témiscamingue region in the Province of Québec, Canada.


Site Access and Existing Infrastructure

The Project is located approximately 38 km southeast of Amos, 15 km west of Barraute and 60 km north of Val-d’Or in the Province of Québec, Canada. The Project is approximately 550 km north of Montréal and is serviced by road, rail, and air.

The town of Val-d’Or, with a population of approximately 32,750 residents (Canadian Census, 2021), is located 60 km south of the Property, along the provincial Highway 111. Since Val-d’Or was founded in the 1920s, it has been a mining service centre. Val-d’Or is one of the largest communities in the Abitibi region and has all major services, including an airport with scheduled service from Montréal. Val-d’Or is a 6-hour drive from Montréal, and there are daily bus services between Montréal and the other cities and towns in the Abitibi region.

The town of Amos, with a population of approximately 12,675 residents (Canadian Census, 2021), is located approximately 38km northwest of the NAL site. Amos is served by highways 109, 111, and 395 and the Amos/Magny airport.

The site is accessible by provincial Highway 111, connecting Val-d’Or and Amos, or alternatively by provincial Highway 397, connecting Val-d’Or and Barraute. An all-weather secondary road, known as Route du Lithium, connecting the site to the Val-d’Or – Amos highway, which was used to traverse the Property and which constrained pit operations, has now been relocated to avoid the mining area. The site is also accessible from Mont-Vidéo, through an all-weather road that connects further east to the Val-d’Or – Barraute highway. Canadian National (CN) railway line is about 49km east of the Property, connecting east through to Montréal and west to the North American rail network.

A high-voltage power line (120 kV) passes approximately 2 km to the west of the Property and a 25 kV electric line, running along the Route du Lithium, services the Mont-Vidéo ski and recreation area.

Geology and Mineralisation

Results of past mineral exploration, resource evaluation and mining demonstrate that NAL is an extensively mineralised lithium system. The primary metal is lithium, and it is mainly associated with spodumene, a lithium bearing pyroxene.

North American Lithium’s pegmatite dykes occupy an area spanning 3,550 m along strike, 1,300 m in width and 800 m in depth. A total of 117 spodumene-bearing pegmatite dykes each with thicknesses greater than 2 m and up to 70 m are open at depth and have been identified in the NAL geological model. Spodumene crystals are widely and variably spread throughout the dykes, displaying faint greenish shades and sometimes locally displaying centimetric to decametric crystal gradations. Pegmatite dykes display internal zoning.

The Project is located in the region of The Archean Preissac-Lacorne syn- to post-tectonic intrusion that was emplaced in the southern Volcanic Zone of the Abitibi Greenstone Belt of the Superior Province of Québec.

Local geological units are summarised in Table 3 and they comprise (from oldest to youngest): basaltic lavas (Malartic and Kinojevis Groups), biotite schist (Kewagama Group), metaperidotite and monzogranite (La Corne pluton).


Table 3 – Geological Units

Geologic Unit Description  
Basaltic Lavas
Malartic and Kinojevis
Groups
2.718 Ma
Volcanic rocks are generally fine-grained and medium to dark green on fresh surfaces. The units are massive or locally exhibit structures such as pillows, flow breccia or amygdule. Under the microscope, the volcanic rocks are mainly green hornblende, plagioclase with minor amounts of quartz, epidote, biotite, and chlorite. Accessory minerals include titanite, apatite, magnetite, pyrite and an alteration product of ilmenite, leucoxene. The abundant green hornblende shows incipient alteration to chlorite or partial replacement by holmquistite.  
Biotite Schist
Kewagama Group
The biotite schists are conformably interbedded with the basaltic lavas. The schists are mainly sedimentary in origin, derived from greywacke, sandstone, and conglomerate. The biotite schist beds are up to 40 cm thick, fine-grained and are grey to black on fresh surfaces. They are foliated with the foliation parallel with either the contact or the foliation in the outcrops of the Preissac-La Corne batholith. Under the microscope, the biotite schist consists mainly of quartz, plagioclase, and biotite. Hornblende and chlorite are major components in a few beds. The common accessory minerals are apatite, epidote, tourmaline, pyrite, and magnetite.  
Metaperidotite The metaperidotite is interbedded with basaltic lavas and, less commonly, with biotite schists. Metaperidotite is fine-grained and black or dark green in colour. The weathered surface is typically brown and exhibits a variety of textures, including polygonal fracture systems, pseudo-pillow structures and a platy structure, which is likely komatiite. The metaperidotite consists mainly of felted aggregates of chlorite flakes, acicular to prismatic actinolite, fibrous serpentine and talc flakes with accessory magnetite, carbonate, and pyrite. The platy structure consists of planar concentrations of chlorite and serpentine, alternating with similarly shaped concentrations of actinolite and magnetite. Primary olivine and/or pyroxene relicts are pseudomorphed by aggregates of chlorite, serpentine, talc, magnetite, and carbonate.  
Granodiorite
La Corne Pluton
2,621-2,655 Ma
The La Corne pluton has been described by Mulja et al. (1995a). It is dominated by biotite monzogranite, which gives way inward to two-mica and muscovite monzogranite. The geology of the La Corne pluton is similar to that of the rest of the Preissac-La Corne batholith.  
Gabbro/Diabase Dykes
Proterozoic age
There are post-batholithic gabbro/diabase dykes that outcrop in the batholith and nearby as tabular bodies up to 60 m wide and several kilometres long, striking either N25º E or N40º E and dipping vertically. The gabbro is fine- to medium-grained and tends to be ophitic.  
   

Mineral Resources and Ore Reserves

The project database contains data from 1,575 diamond drillholes surfaces and underground collared, spanning a total of 27,183 records of Li2O assays with a mean sample length of approximately 0.884 m. Li2O grade varies from 0.000% to 5.318%. Global average Li2O grade for raw samples (excluding 0.00% assays) is 0.783%. From this database, a subset of 562 surface collared drillholes totalling 153,047 m was used for the Mineral Resource estimate.

The current Mineral Resource Estimate and Ore Reserve Estimate are presented in Table 4 and Table 5 below. The Mineral Resource and Ore Reserve estimates were prepared by Competent Persons in accordance with the 2012 JORC Code.


Table 4 – North American Lithium – Mineral Resource Estimates (0.60% Li



2



O cut-off grade for the RPEEE pit and 0.70% Li



2



O cut-off grade for underground domain)

Resource
Classification
  Method Tonnes (Mt)   Li

2

O Grade (%)
  Cut-Off Grade (%)  
Indicated   Open Pit 76.2   1.17   0.60  
Inferred   Open Pit 8.6   1.13   0.60  
Indicated   Underground      
Inferred   Underground 10.3   1.01   0.70  
Total     95.0   1.15      
   


Table 5 – North American Lithium – Ore Reserves Estimate, as at of June 30, 2025

Resource Classification Tonnes (Mt)   Li

2

O Grade (%)
  Cut-Off Grade (%)   Fe Grade (%)  
Proved Ore Reserves 0.3   1.01   0.60   1.55  
Probable Ore Reserves 48.2   1.11   0.60   0.82  
Total 48.6   1.11   0.60   0.83  
 

The information on Mineral Resources and Ore Reserves is extracted from the announcement entitled “NAL Resources and Reserves Increases” published on the ASX on August 27th, 2025, and is available to view on the Elevra’s website on the ASX. The company confirms that it is not aware of any new information or data that materially affects the information included in the original market announcement and, in the case of estimates of Mineral Resources or Ore Reserves, that all material assumptions and technical parameters underpinning the estimates in the relevant market announcement continue to apply and have not materially changed. The company confirms that the form and context in which the Competent Person’s findings are presented have not been materially modified from the original market announcement.

Mine Design

The NAL final pit design was based on a pit optimisation assessment which determined the economic limits of the deposit. The in-pit haul road has been designed on the hanging wall side of the deposit to maximise ore recovery within the pit shell, provide more direct access to the waste storage facilities and ROM and to provide access for the final mining pushback. The final pit reaches a maximum depth of approximately 380m below topography.

The life-of-mine schedule was completed based on a plant throughput authorised at 4,500 tonnes per day. The initial daily processing rate is 3,780 tonnes per day, which is maintained up to July 1st, 2027. The daily processing rate increases to 4,500 tonnes per day annual average from 1st of July 2027 and increases again to 6,500 tonnes per day annual average from 1st of April 2028. Ore mining out of the pit is limited to 4,700 tonnes per day annual average until 1st of April 2028, before increasing to maximum of 7,000 tonnes per day annual average.

The final pit design was subdivided into a total of seven mining phases, with the physicals and ore grades contained within each phase shown in Table 6. Special attention was given to the historical underground openings when setting the physical limits for every phase, with consideration taken to ensure that the phase walls did not intersect the old workings. The current life-of-mine plan will be clear of all historical underground workings by the end of 2030.


Table 6 – NAL Physicals by Phase

Item   Units   Total   Phase 2   Phase 3   Phase 4   Phase 5   Phase 6   Phase 7   Phase 8  
Total In-Pit   Mt   388.2   0.2   33.2   55.0   55.9   47.3   182.0   14.7  
Waste Rock   Mt   340.8   0.2   27.8   47.6   49.8   40.3   162.2   13.0  
ROM Ore   Mt   47.5   0.01   5.4   7.3   6.1   7.0   19.9   1.8  
Lithium
Grade
  % Li2O   1.11%   1.14%   1.13%   1.09%   1.05%   1.22%   1.10%   1.04%  
Iron Grade   % Fe   0.82%   0.59%   0.89%   0.91%   0.85%   0.75%   0.79%   0.71%  
Strip Ratio   twaste: tore   7.2   11.2   5.2   6.5   8.2   5.8   8.2   7.3  
 

The following criteria were applied during the phase design construction:

  • Minimum mining width of 60m considered between phases on the surface and 40m at the phase base;
  • Ease of access to different mining areas;
  • Mining and processing production rate; and
  • Physical constraints posed by historical underground workings.

Two life-of-mine schedules were developed for the updated scoping study using Micromine’s Spry software package. The two schedules were:

  • A base case schedule utilising a processing rate of approximately 3,780 tonnes per day; and
  • An expanded case schedule, with three stages of capital investment gradually increasing the processing production rate up to 6,500 tonnes per day.

Both schedules utilised the same reserves set and dump designs, however due to differing production rates, the schedules finished at different times. The base case schedule ran until 2061, whilst the expanded case schedule was finished in 2047.

For both cases, the LOM schedule utilised similar class equipment that is currently operating at site, with a large 200t excavator added to the fleet to assist with maintaining the required stripping quantities.

The key highlights of the LOM plan are summarised as follows:

  • Mine life of 35 years for the base case and 21 years for the expanded case.
  • Total of 47.5Mt of ore mined.
  • Total of 340.8mt of waste mined, leading to an overall strip ratio of 7.2:1, which fluctuates over the years.
  • Crusher feed averages 1.36mt and 2.37mt per annum for the base case and expanded case respectively when operating at full capacity.
  • In the base case, crusher feed grade fluctuates from 0.91% Li2O to 1.13% Li2O on a yearly basis over the LOM, reaching its maximum value in Year 2058.
  • In the expanded case, crusher feed grade fluctuates from 0.92% Li2O to 1.22% Li2O on a yearly basis over the LOM, reaching its maximum value in Year 2045.


NAL Expansion Concentrator Feed and Production Profile

The Updated Study production schedule is based solely upon current NAL Ore Reserves as of June 30, 2025.

The NAL Expansion concentrator ore feed will be blended at the ROM to control Li2O grade and Fe contamination. The average head grade is 1.11% Li2O over the LOM. Figure 5 presents yearly head feed tonnage and grade over the LOM

The NAL Expansion increases the total process plant throughput to approximately 2.4 Mtpa with a process plant availability of 90%. Based on the LOM Plan, the circuit will on average produce a nominal 338 ktpa of spodumene flotation concentrate, with a 71.2% Li2O recovery at a target product grade of 5.4% Li2O once the expansion circuit is fully operational.

Metallurgy

The NAL deposit has undergone extensive metallurgical test work. Metallurgical recovery assumptions are based on historical metallurgical tests and test work completed during 2018 – 2023. Test work programs began in 2008 to establish the metallurgical character of the orebody, to allow the development of a process flowsheet, to test that flowsheet, to evaluate the impact of head grade on performance, and then to produce the engineering data for plant design. This test work occurred under the supervision of independent QPs and Sayona representatives.

The test work evaluated a number of processing techniques including flotation, DMS, LIMS and ore sorting. The progression of this test work took the form of batch scale tests looking at flotation, DMS and grindability leading to locked cycle tests and then pilot scale continuous tests. WHIMS and DMS were not included in the original flowsheet based on the outcomes of the test work. The test work outcomes formed the design basis of the NAL concentrator that commenced operation in March 2013 but ceased operation in September 2014. This was principally due to higher than anticipated mining dilution of the ore with host rock, and lower than target spodumene recovery and concentrate grade.

Subsequent test work programs were undertaken to characterise and mitigate the effect of the dilution including hardness testing and WHIMS test work (on both plant samples and pegmatite samples of varying levels of dilution of the two major dilution host rocks). The impact of the WHIMS on flotation was also examined, and the final spodumene flotation concentrate was 6% Li2O at an estimated test work recovery of 80 to 83%.

Modifications were made to the plant based upon this test work with the addition of WHIMS units prior to flotation and additional ore sorting capacity on the feed. The plant was restarted in 2017 following these changes and consistently achieved concentrate grades of 5.4 to 6.0% Li2O at recoveries from 55 to 70%. The plant subsequently shutdown due to market conditions prior to name plate capacity being achieved.

Further modifications were made to the plant prior to the restart in 2023, but these were focused on operational issues identified from the previous operation rather than underlying metallurgical issues relating to the ore. (i.e. capacity related).

Historical metallurgical test work from the above-described previous phases, along with current operational performance has been used as the basis for the NAL expansion scoping study.

Based on the previous laboratory test work and current operational performance, an average global recovery of 71.2% at a spodumene concentrate grade of 5.4% Li2O has been applied across the NAL Mine Plan for the purposes of the updated scoping study.

The impact of ore sorters was analysed through statistical methods for impact on recovery from operating data. A recovery increase of 2% above the base case is included in the above 71.2% with additional ore sorting performance testing underway.

Mineral Processing and Flowsheet

NAL’s current operations are authorised at 4,500 tpd average annual milling throughput for the processing plant for production of spodumene concentrate. The NAL facility consists of the following distinct areas:

  • The primary, secondary and tertiary crushing, and ore sorting circuits to produce an upgraded plant feed for downstream processing.
  • The spodumene processing plant including grinding, desliming, magnetic separation, flotation and dewatering circuits to produce a final spodumene concentrate.
  • Process water and utilities circuits including tailings thickeners, reagents preparation, reverse osmosis treatment, and tailings management.

In addition to the areas described above, the processing plant includes an area historically designated for the conversion of the spodumene concentrate into lithium carbonate. The existing carbonate facility is not functional and there are no plans to produce lithium carbonate at the NAL facility.

The Updated Scoping Study expansion design follows the staged approach identified by Elevra to reach the following authorised mill throughputs:

  • Stage 1: Increase to the limits of the current milling permit at 4,500 t/d average annual rate.
  • Stage 2: Expansion to a new milling throughput limit of 6,500 t/d average annual rate.

The expansion targets will be achieved through the following modifications to the existing facility:

  • Stage 1: Plant optimisation
    • Addition of lump breakers in the crusher circuit to prevent ice lumping of the ore
    • Addition of stacksizers to the existing ball mill unit
    • Optimisation of the desliming and magnetic separation circuit
    • Addition of flotation conditioning tanks
    • Refurbishment of lithium carbonate filters for new dewatering unit
    • Addition of a new flotation thickener circuit
    • Addition of pumping capacity to TSF
  • Stage 2: Plant expansion  
    • Contracting of a temporary crusher to balance plant feed with existing crusher
    • Addition of a second ball mill line including stack sizers and trash trommel
    • Addition of a third magnetic separation line
    • Addition of a new rougher unit and conversion of the existing rougher to scavenger duty
    • Addition of a second process thickener to increase capacity
  • Stage 3: New crusher construction  
    • Construction of new crusher and new fine covered ore stockpile complete with reclaim
    • Conversion of the existing crusher circuit to an ore sorting facility

Table 7 provides a high-level overview of the main design criteria.


Table 7 – General Process Design Criteria

Criterion   Unit Base Case   Stage 1   Stage 2   Stage 3  
Crushing Plant Availability   % 65   65   65   65  
Processing Plant Availability   % 90   90   90   90  
Total ROM Crusher Feed   t/d 5,815   6,923   10,000   10,000  
Total Processing Plant Feed   t/d 3,780   4,500   6,500   6,500  
Plant Feed Li2O Grade   % 1.01   1.01   1.01   1.01  
Target Concentrate Li2O grade   % 5.40   5.40   5.40   5.40  
Target Plant Li2O recovery   % 69.00   71.20   71.20   71.20  
 
Note: all parameters are nominal rating unless noted otherwise
 


Ore Crushing and Sorting

The current crusher will continue regular operations during Stage 1 and Stage 2. It is expected that the crusher capacity can be increased to meet the 15-20% increase required for Stage 1 without any expansion. Due to reported issues with ice lumps forming in the fine ore silo due to the cold weather conditions, lump breakers will be installed at the outlet of the silos to ensure the quality of the plant feed. A temporary contract crusher will be required in Stage 2 to balance the requirements of the processing plant after the expansion.

In Stage 3, the existing crusher will be repurposed as a dedicated ore sorting facility once the new crusher is operational. This part will be done after Stage 2 is completed. This ore sorting unit will increase the operation’s flexibility, as well as simplify the design and reduce the capital cost of the new crusher facility. The existing ore sorters will be replaced with XRT ore sorters, which use the density of the particles as opposed to the surface properties.

Sorted ore and fresh ore from the ROM is discharged to the new Stage 3 crusher through a 90 mm aperture vibrating grizzly, with oversize feeding a jaw crusher. Primary crusher product will be conveyed to a double deck banana screen, with a top deck aperture of 50 mm and a lower deck aperture of 20 mm. The top deck oversize will be conveyed to the secondary cone crusher, and the bottom deck oversize material will be conveyed to the tertiary cone crusher. The crushed product will be conveyed back to the double deck screen for re-sizing. Crushed product underflowing the double deck screen will have a nominal size (F80) of <13 mm and will be conveyed to a new fine ore stockpile.


Concentrator

Modifications to the concentrator will be made during Stage 1 and Stage 2.

The Stage 1 plant process flow is as follows:

  • Fine ore is fed to the grinding circuit via conveyor at a rate of 4,500 tpd from the fine ore silo.
  • The grinding circuit consists of primary open circuit rod mill followed by a ball mill working in a closed circuit with nine stack sizers (six existing, three new to be procured). The oversize with a nominal P80 of 970 microns is returned to the ball mill.
  • The stack sizer undersize at a nominal P80 of 200 microns is sent to the desliming cyclone to remove slime material. The overflow slime material reports to the process thickener.
  • The cyclone underflow is sent to the magnetic separation circuit which consists of two parallel lines each including a low-intensity magnetic separator (LIMS) and a primary wet high-intensity magnetic separator (WHIMS) in series. The intermediate non-magnetic product from the two lines is combined and sent to two parallel secondary WHIMS. The magnetics extracted by all stages are combined and pumped to the process thickener.
  • The non-magnetic slurry is fed to a desliming cyclone to reach a solids concentration of 65% in the underflow. The overflow is sent to the flotation thickener. The underflow undergoes two-stage rougher conditioning followed by rougher flotation (3 cells total). The rougher tails are further deslimed and conditioned before scavenger flotation (3 cells total). The scavenger tails are sent to the flotation thickener.
  • The concentrate from the rougher and scavenger stages is combined and sent to cleaner flotation (31 cells total). Cleaner flotation tails are sent to a classifier cyclone with the underflow returned to the ball mill and the overflow sent to the process thickener. The cleaner tails concentrate is pumped to the concentrate storage tank which serves as a buffer between the upstream process and the downstream filtration.
  • The dewatering unit consists of a concentrate dewatering cyclone followed by a concentrate scavenger cyclone with two parallel vacuum belt filters (1 Duty/1 Standby). The purpose of the scavenger cyclone is to recover misreported material from the dewatering cyclone and vacuum filters. The spodumene concentrate is dewatered to a final moisture content of 6%.

The Stage 2 plant process flow is as follows:

  • Fine ore is fed to the grinding circuit via conveyor at a total rate of 6,500 tpd by a combination of the existing crusher and a temporary contract crusher.
  • The grinding circuit consists of a primary open circuit rod mill distributing to two parallel lines of ball mills each operating in a closed circuit with stack sizers. The first line is the Stage 1 ball mill with nine stack sizers, the second line is a new ball mill with six dedicated stack sizers. Although the design considers procurement of six new stack sizers for Stage 2, there is an opportunity to reuse the three stack sizers procured in Stage 1 for the second ball mill.
  • The stack sizer undersize from the two ball mill lines is collected and screened through a trash trommel to remove product over 1 mm. The trommel undersize is sent to the desliming cyclone to remove slime material. The desliming cyclone targets a cut point (D50) of 10 µm. The overflow slime material reports to the process thickener.
  • The underflow is sent to the magnetic separation circuit which now consists of three parallel lines each including a LIMS and a primary WHIMS in series. The intermediate non-magnetic product from all three lines is combined and sent to two parallel secondary WHIMS. The final non-magnetic slurry is collected and sent to the flotation circuit. The magnetics extracted by all stages are combined and pumped to the process thickener.
  • The non-magnetic slurry is fed to a desliming cyclone to reach a solids concentration of 65% in the underflow. The cyclone overflow is returned to the trash trommel. The underflow is sent to new two-stage rougher conditioning tanks followed by a new rougher flotation circuit (5 cells total). The first stage of rougher flotation consists of two cells in parallel and individual cell level control to ensure the effectiveness of the flotation. Tails from the first stage is sent to the second stage of rougher flotation. The concentrate from the rougher is sent to cleaner flotation.
  • The tails from the second stage rougher are sent to two lines of scavenger flotation (2 x 3 cells). Each scavenger line is preceded by a scavenger cyclone and two-stage conditioning. The cyclones overflow and scavenger cells tails are sent to the flotation thickener. The scavenger concentrate is returned to cleaner flotation.
  • The remaining steps for the cleaner flotation and dewatering are unchanged from Stage 1.


Lithium Concentrate Storage

The final 5.4% spodumene concentrate is stored in a new stockpile in a new enclosed area of the plant in the location of the carbonate calciner. The stockpile will have a capacity for 72-96 hours and have truck access for loading of the product.


Tailings Management

The processing plant will operate under separate process water and flotation water circuits. This design will isolate water contaminated with flotation reagents from sensitive equipment such as the LIMS and WHIMS.

The process water circuit consists of two thickeners and receives the following tails streams:

  • Slime material from primary desliming
  • Magnetic material from magnetic separation (LIMS and WHIMS)

The flotation water circuit consists of a single thickener and receives the following tails streams:

  • Slime material from cleaner classification
  • Scavenger flotation tailings
  • Scavenger dewatering tailings

These combined tailings are thickened to 50% w/w solids with the aid of an anionic flocculant. The underflow is pumped to the TSF for disposal. The overflow reports to the respective water circuits.


Concentrator Production and Recoveries

The expansion is scheduled to treat an annual average rate of 6,500 tpd of blended ore.

The existing crusher, ore sorting, new crusher and ore storage areas are designed to operate with an availability of 65%. The processing plant, including the grinding, classification, desliming, magnetic separation, flotation and dewatering units, is designed to operate at 90% availability. The processing plant will operate on a 24-hour per day and 7 days per week basis.

The recovery benefits will all be achieved in Stage 1. The modifications brought in Stage 2 are designed to increase the plant throughput to 6,500 tpd and improve operational stability and flexibility though the rougher circuit optimisation. The recovery benefits from the existing operation will come from the following flowsheet changes:

  • Improved flotation feed sizing
  • Improved magnetic separation circuit (LIMS and WHIMS)
  • Improved flotation conditioning
  • Improved cleaner tails handling

To help confirm and support the design parameters used in this updated scoping study, the following works are on-going:

  • Plant trials on operating the existing WHIMS in parallel configuration
  • Flotation conditioning tests
  • Surveys and simulations to assess the new flotation feed particle size distribution (PSD) and slimes generation

Tailings Storage Facilities

The mine plan for NAL forecasts mining operations continuing beyond the capacity of the existing Tailings Storage Facility (TSF) No. 1. The current site includes a conventional tailings pond (TSF-1) as part of the tailings management infrastructure, located 500 m south of the processing plant.

A second TSF (TSF-2) is required to encompass the current base case LOM. TSF-2 was originally envisaged as a dry tailings deposition management concept. After conducting an analysis of different mining residue disposal technologies, the choice of wet disposal was previously confirmed for the existing NAL operation over the duration of the existing LOM.

The recently published Ore Reserves require new waste management facilities (e.g., waste rock and tailings) to accommodate the volumes associated to these new reserves. The additional tailings will be managed in a new tailings facility (TSF-3). A preliminary location has been identified and design for TSF-3 has been undertaken for the purposes of the updated scoping study. The final location of the tailings and waste rock management facilities will be confirmed through a detailed Variant Analysis that will be conducted through future phases of studies. Total tailings to be managed by the facilities over LOM is 41.8Mt.

Results from previous geochemical studies showed that waste rock is neither Acid Rock Draining (ARD), nor Metal Leaching (ML); therefore, no indication that special requirements are required by the Ministère de l’Environnement, de la Lutte contre les Changements Climatiques, de la Faune et des Parcs (MELCCFP) for stockpiling and water management. Additional tailings and waste rock characterisation test work is planned during the next phase of the project.

Infrastructure

Site infrastructure at the NAL operation is established and operating, the expansion requires additional infrastructure as outlined below.

The current site infrastructure includes:

  • Open pit.
  • Processing plant and ROM ore pad.
  • Waste rock and overburden storage areas (WR#2, WR#3 & OB#1).
  • Conventional tailings pond (TSF-1).
  • Administration facility, including offices and personnel changing area (dry).
  • Workshop, tyre change, warehouse, and storage areas.
  • Fuel, lube, and oil storage facility.
  • Reticulated services, including power, lighting and communications, raw water and clean water for fire protection, process water and potable water, potable water treatment plant, sewage collection, treatment, and disposal.
  • Crushed ore dome.
  • Access roads.
  • Water management infrastructures.

Additional infrastructure required for the expansion include:

  • Expansion of the open pit.
  • New crushing and ore sorting circuit including crushed ore dome.
  • New grinding, magnetic separation and flotation.
  • Concentrate dewatering filters.
  • Tailings thickening.
  • Concentrate storage building by extending the existing building.
  • Additional mechanical workshop, operation room, and supervisor offices.
  • Additional tailings management facilities:  
    • TSF-2 (required for base case and expansion)
    • TSF-3 (required for base case and expansion)
  • Additional waste stockpile area (HST#4) and associated water management structures.
  • Multi-service buildings:  
    • Additional offices, engineering, administration etc.
    • Additional capacity for the mine change rooms, showers and ablutions.
    • Additional mine offices and mining dispatch control room.
  • Mine maintenance shop:  
    • Two additional mining service bays.
    • Additional warehouse storage.
    • Additional supervisory and administration offices.
    • Wash bay.
  • Auxiliary buildings:  
    • Warehouse domes.
    • Relocation of the mine fuel depot and additional capacity. (Required for base case and expansion)


Power Supply and Distribution

Power for the Project is taken at 120 kV from a transmission line owned by the provincial utility company, Hydro Québec. This transmission line runs on the west side of the Project site and the spur feeding the plant is approximately 600m long.

Power supply will be subject to additional request to the utility for the power. Stage 1 expansion falls within current contract limits whereas Stage 2 and 3 will require approval from the Ministère de l’Économie, de l’Innovation et de l’Énergie (MEIE) and studies by Hydro Québec. Coordination is currently underway to process the forecasted increase.


Water Management

The Project has no infrastructure in place to draw water from any external source for processing purposes and the expansion does not require the installation of water drawing infrastructure. Groundwater and run-off from the mine pit are recovered for use as fresh water in the process plant. All water used in the concentrator is recycled internally or is reclaimed from the tailings ponds, where levels must be managed seasonally.

To support the NAL expansion, a site-wide water balance was performed based on major infrastructure expansion footprint. The water balance shows an excess of water on the overall site for all stages of development. To manage future water balance, infrastructure such as basins and drainage ditches have been incorporated into the expansion project.

Environment and Social

The NAL project has existing environmental permits for mining operations including the disposal of waste rock, storage of tailings, drawing water for processing and the release of treated water to the environment. Elevra is currently operating in accordance with existing approvals by provincial and federal authorities. The processing plant has approval for throughput of 4,500 tpd. Elevra has received confirmation from both the provincial and federal governments that the project to expand the plant’s capacity (Stages 1 & 2) including the new crushing area in Stage 3, are not subject to environmental assessments.

The expansion of the mining lease involving the removal of Lake Lortie will be subject to an environmental assessment process. This requires that an Environmental and Social Impact Assessment (ESIA) be submitted for review by the Bureau d’Audiences Publiques sur l’Environnement (BAPE). Provincial authorities have confirmed that only the removal of Lake Lortie and its associated infrastructure (TSF#3 & HS#4) will be subject to environmental assessment procedures. The extension of mineral resources under Lac Lortie will require the approval from the Ministère des Ressources Naturelles et des Forêts (MRNF) for the expansion of the existing mining lease, after the ESIA process. The MRNF will require an update to the Closure and Rehabilitation Plan and the update of the approval by the Ministère de l’Environnement, de la Lutte contre les Changements Climatiques, de la Faune et des Parcs (MELCCFP) of the environmental authorisation. The two authorisations must be obtained before the extension mining lease can be granted. Also, the process for authorising the extension of the mining lease includes consultation with the Communities of Interest (COI). This process includes public consultations, including First Nations, that will allow the communities to provide feedback regarding the expansion project. This step will be facilitated by the environmental assessment process conducted by the BAPE.

The Department of Fisheries and Oceans Canada (DFO) will require that effects of mining activities on the fish habitat in Lake Lortie be offset by an approved habitat compensation project. Consultation will be undertaken with First Nations in design of the compensation project.

The NAL site is located in a recreational zoning class of the Municipality of La Corne as defined under local by-laws. This zoning allows mining activities; however, consultation will be undertaken to ensure community acceptance with the aim to minimise impact on local recreational and tourism activities. Any possible effect on the Harricana moraine will be documented.

The increase in ore processing capacity is below the threshold for triggering both provincial and federal impact assessments. Both the plant’s processing capacity and the footprint of the new mining infrastructure are below the 50% increase threshold allowed under Canadian law. The environmental impact of additional mining activities (tailings management facilities, mine waste rock dump, etc.) will be evaluated during the next phase of studies.

A former tailings facility, under the responsibility of the Province of Quebec since 2010, is located within the mineral resource footprint. The management of tailings from previous mining operations are subject to specific conditions, depending on their geochemical characteristics. The MRNF has stated in 2010 that these tailings do not show acid rock drainage potential. However, the MELCCFP requirements for geochemical characterisation have increased since 2020 and a more comprehensive characterisation will be required.

Finally, the responsibility for historical infrastructure will be assessed and discussed with the MRNF as additional resources beyond current permits are accessed.

Project Schedule and Implementation

The project schedule will be based on the project development sequence identified by Elevra in the previous ASX press release “Accelerated NAL Expansion” published on January 12th, 2026. The following dates were identified for the delivery of the three Stages:

  • Stage 1: An initial 15-20% increase in annual spodumene concentrate production above current production levels commencing in mid-CY27 with an incremental reduction in unit operating costs. This increase is within the current limits of the milling permit, which is set at 4,500 tpd;
  • Stage 2: A subsequent expansion of downstream milling, flotation and filtration capacity to 6,500 tpd with an anticipated corresponding concentrate production rate of 338 ktpa post expansion. The incremental feed material will be processed using a temporary mobile crushing circuit operating in conjunction with the existing crushing circuit. The further expanded production is expected to commence early CY28, with an additional incremental reduction in unit operating costs; and
  • Stage 3: The replacement of the temporary mobile crushing circuit and the existing crushing circuit with a new crushing circuit capable of meeting feed requirements for a LOM average production of 338 ktpa post expansion. This final step is expected to be completed in early-CY29 and is expected to deliver crushing cost efficiencies required to meet the anticipated LOM cost reduction.

Engineering will continue following the updated scoping study. As outlined in the January 12th 2026 ASX press release, Elevra plans to move directly to detailed engineering to advance Stage 1 and Stage 2.

A preliminary project schedule was developed. Further development and detailed execution planning will be undertaken in the next project phases.

Capital and Sustaining Expenditures


Basis of Estimate

This estimate was developed to meet the minimum requirements of a Class V estimate as defined in AACE International (Association for the Advancement of Cost Engineering) recommended practice no. 18R-97.

The CAPEX estimate has an intended accuracy of ± 40%. Some individual elements of the estimate may not achieve the target level of accuracy; however, the sum of all estimation elements falls within the parameters of the intended accuracy.

The work includes major demolition, and modifications work in the existing plant to allow the increase of capacity as well as addition of new equipment.

The scope included a three-staged approach to increase the capacity of the plant. The main scope can be summarised as following:

  • Optimisation to 4,500 tpd – ramp-up starting mid-2027.
  • Optimisation within existing process plant to 6,500 tpd (with existing crushing circuit, adding temporary mobile crushing) – ramp-up starting early 2028.
  • Final expansion scenario at 6,500 tpd includes new crushing circuit (and ancillary infrastructure) – ramp-up starting early 2029.
  • In addition to contingency, allocations have been made to allow potential additional comminution (rod mill unit) capacity in the plant. These costs may be released once final testing is completed and a decision made on the need for additional capacity.


Capital Costs

The total Direct and Indirect capital expenditures (CAPEX), including contingencies, required to bring the Project into production is estimated to be CAD$ 365.7M. Table 8 below presents a summary and breakdown of the capital costs including contingencies.


Table 8 – Summary of Total Expansion CAPEX by Discipline

Area Stage 1 ($M CAD)   Stage 2 ($M CAD)   Stage 3 ($M CAD)   Total ($M CAD)  
Mechanical Direct $
16.5
  $
16.7
  $
29.6
  $
62.8
 
Mechanical $16.5   $16.7   $29.6   $62.8  
Other Disciplines Direct $
40.4
  $
29.1
  $
81.1
  $
150.6
 
HVAC $0.8   $0.8   $3.0   $4.6  
Platework $0.6   $1.1   $9.8   $11.5  
Civil $1.7   $0.8   $4.4   $6.9  
Piping $4.1   $4.2   $1.5   $9.8  
Concrete $7.4   $6.7   $17.4   $31.5  
Structural $7.4   $6.7   $19.1   $33.2  
Building $2.7   $0.5   $10.1   $13.3  
Electrical $6.6   $6.7   $11.9   $25.1  
Instrumentation &
Controls
$1.7   $1.7   $3.0   $6.3  
Demolitions $7.3   $-   $-   $7.3  
Mobile Equipment $-   $-   $1.0   $1.0  
Indirect Costs $
17.3
  $
16.7
  $
33.9
  $
67.9
 
EPCM Services $9.1   $7.3   $17.7   $34.1  
Construction – Indirect $3.4   $2.7   $6.6   $12.8  
Owner’s Costs $2.3   $1.8   $4.4   $8.5  
Operational Readiness
& Pre-Production Labour
$0.3   $3.0   $1.2   $4.6  
Insurances $0.9   $0.7   $1.7   $3.2  
Spares Strategic $0.6   $0.5   $1.1   $2.1  
Spares Commissioning $0.2   $0.2   $0.4   $0.9  
Transport / Delivery to Site $0.3   $0.3   $0.3   $1.0  
First Fill $0.2   $0.1   $0.3   $0.6  
Total Before Contingency $
74.1
  $
62.5
  $
144.6
  $
281.3
 
Contingency P50 (30%) $
22.2
  $
18.8
  $
43.4
  $
84.4
 
Total CAPEX $
96.4
  $
81.3
  $
188.0
  $
365.7
 
                 


Sustaining Capital

The sustaining capital (SUSEX) for the base case and expansion project was estimated using current operational budgets and factors of direct plant cost. Tailings SUSEX costs were derived using previous estimates and quantities applied over preliminary facility designs. The expansion case includes additional sustaining costs for additional equipment which are offset by the shorter mine life of this scenario. The SUSEX summary is presented in Table 9.

The existing crushing circuit will be repurposed into an ore sorting facility following the Stage 2 expansion. This change in the design will increase the sustaining capital compared to the previous scoping study.

Environmental costs related to the Project include:

  • Compensation for loss of wetlands and water bodies.
  • Compensation for loss of fish habitats.
  • Compensation for loss of forest land.

The SUSEX summary is presented in Table 9.


Table 9 – Summary of Sustaining Capital

Area Base ($M CAD)   Expansion ($M CAD)  
Tailings $351.2   $351.2  
Stay in Business Capital (SIBC) $105.4   $126.2  
Mining $23.3   $23.3  
Compensation $25.6   $25.6  
Total SUSEX $
505.6
  $
526.4
 
 


Closure Cost

Closure and rehabilitation costs include a post-closure monitoring/inspection program, engineering, contracts, supervision, reporting, removal of Project infrastructure, (i.e., ponds, buildings, electrical poles, tanks, roads, etc.), and site restoration activities as per the Project site restoration plan submitted to governmental agencies.

The closure cost estimate was updated from 2024 closure cost as accepted by Ministry using the same cost per unit. The concept of closure remains unchanged from the previous closure plan. Additional areas were considered for the reclamation of TSF#3, HS#4. Reserves closure cost also includes an additional amount for demolition and restoration of crushing and mill expansion.

Reclamation and closure costs for the Expansion Project have been evaluated to be C$62.4M, increased from the C$60.4M base case.

Operating Expenditures

The operating cost estimate (OPEX) for the base and expansion cases are calculated from NAL operating budgets. The base case includes a nominal feed rate of 3,780 tpd while the expansion case accounts for the associated increase in feed to 4500 tpd followed by the further increase to 6,500 tpd.

The OPEX was developed in accordance with the requirement of a scoping level study with a nominal accuracy range of ± 20%. The level of estimation is supported by actual operational information including salaries, consumables, maintenance costs and established contracts and therefore are more precise given this is a brownfield project.

The OPEX results represent annual steady state operations therefore no escalation or inflation is included within the estimate. A summary of the average LOM OPEX costs (all values in CAD$) and comparison between scenarios can be found in Table 10. OPEX costs are evaluated commencing as of Fiscal Year 2027.


Table 10 – Total OPEX Summary

Item   Units   Base   Stage 1   Stage 2   Stage 3  
LOM   Yrs   35       21      
Milling Rate   Mt/yr   1.3   1.6   2.4   2.4  
Mining Cost (ore & waste)   C$/t mined   8.9       7.6      
Processing Cost   C$/t milled   42.6   38.7   38.8   33.4  
G&A   C$M/yr   23.6   24.6   28.3   29.9  
Transport Cost   C$/t dry conc   142.1   133.8   118.6   118.6  
Total OPEX   C$M   7,203       5,943
     
C1 Cost Concentrate   C$/t dry conc   1,076       868
     
 

The C1 Cost reductions are driven by the impact of increased tonnage of concentrate, processed and mined, compared to the base case. The reductions in cost are categorised in four broad categories:

  • Reduction in G&A per tonne processed resultant from relatively fixed costs between stages with minor adjustments required for additional head count, insurance and employee benefits.
    • 13% reduction in Stage 1
    • 30% reduction in Stage 2 (Includes contract crusher that will be terminated in Stage 3)
    • 26% reduction in Stage 3 (Health and Safety, Human Resources and Environmental costs)
  • Reduction in transport costs per tonne of dry concentrate directly related to increased movement of material compared to elements that are fixed costs. Improvements in material handling on site with new concentrate loading facility reducing on site tramming of material and material loadout.  
    • 6% reduction in Stage 1
    • 17% reduction in Stage 2 (Improvement in contract rates due to increase in volume)
    • 17% reduction in Stage 3 (Same volume as Stage 2)
  • Reduction in processing cost driven mostly by relative low increase in head count required, addition of line power reticulation replacing diesel generators on site for pumping. Power costs and reagents have no impact between the stages as same unit rates are used. Fixed costs from the base case not impacted by the stages provide the remainder of improvements.  
    • 9% reduction in Stage 1
    • 9% reduction in Stage 2 (No change in overall reduction due to contract crusher)
    • 22% reduction in Stage 3 (Operation of new crusher)
  • Reduction in mining costs are estimated based on increased volume, use of larger shovels in waste and benefits from fixed management and administration costs relative to increased tonnage for both contractor and owner costs. Unit rates are based on current operating costs and incorporate an increase in unit rate as mining goes deeper in a similar manner as used for the establishment of the reserves. In the expansion scenario the LOM cost drops from $8.90 to $7.60 or 15% decrease. Current work is underway to incorporate unit fuel burn rates, unit rental rates and adjusted Elevra mining support costs to improve the quality of the mining costs.


Labour

All mine, processing plant and administration site staff personnel work 10-hour shifts on a 4 on / 3 off basis. Contracted mine operations will work 12-hour shifts. For the processing plant, operations and maintenance crews will work two 12-hour shifts. There will be four shift crews rotating on a 7 on / 7 off schedule.

Staffing requirements are built as bottom-up and based off existing operations. The main increases in labour between the base and expansion case are summarised from operational site roles. The plant increase covers the most significant increase which is attributable to additional operators for grinding and flotation extensions as well as increased maintenance (mechanical / piping / electrical / instrumentation). Mine technical services are augmented to cover increased throughput, assay treatment and geology support. G&A costs are impacted by an increase in site support for Health and Safety, Environment and Increased Surface and Warehousing support.


Table 11 – Staff and Hourly Count (Elevra Employees)

Area Base   Stage 1   Stage 2   Stage 3  
G&A 59   60   65   70  
Plant 126   132   150   172  
Mine 40   40   51   51  
Total 225   232   266   293  
 


Power

Power is estimated from current power consumption with rates as per contracted supply with Hydro Quebec scaled for the additional throughput. Power is calculated to account for $2.0/t processed for the base case and all Stages. In further studies the benefits of a complete load study will allow for closer estimate of power savings given the expansion.


Reagents

Reagent costs are calculated from NAL’s current operating contracts with consumptions escalated for the additional throughput.

Market and Lithium Price

Global lithium supply is set to expand strongly in 2026 despite low prices throughout most of 2025. Global demand for lithium products is projected to rise by 20% in 2026 with batteries remaining the principal driver, with electric vehicles accounting for approximately 75% of this demand. Energy storage system demand continues to accelerate at pace, forecast to expand to 328kt LCE, while industrial demand is estimated to be ~210kt LCE, with 50% of that in China.

As a result, prices are forecast to experience upward pressure over 2026 and 2027.

The updated scoping study utilises BMI Q1 2026 base case price scenario. In the short-term, prices for 6% spodumene concentrate (SC6) are forecast to fluctuate between US$2,181/t (2026) and US$1,260/t (2031), with an average price of US$1,664 per tonne through to 2032. The long-term price after 2035 is US$2,430/t.

Financial Analysis

The main highlights of the Project’s financial analysis are presented in Table 12 and Table 13. Financial Analysis was performed commencing as of Fiscal Year 2027.


Table 12 – Main Financial Assumptions and Results Summary for the NAL Expansion Project

Parameters   Unit   Base   Expansion  
Average Price 6% Li2O   USD$/t   $2,261   $2,154  
Life of mine (from FY2027)   yrs   35   21  
Total Waste   Mt   335   335  
Total Ore   Mt   47   47  
Strip Ratio     7.2   7.2  
Average Annual ROM   Mt/y   1.3   2.4  
Average Feed Grade   % Li2O   1.11%   1.11%  
LOM 5.4% Li2O Produced   Mt   6.72   6.85  
LOM Average Annual 5.4% Li2O   kt/y   192   326  
Average Annual 5.4% Li2O production (post
expansion)
  kt/y   194   338  
 


Table 13 – Project Economics

Parameters   Unit   Base   Expansion  
Exchange Rate   CAD/USD   1.35   1.35  
Mining Cost (ore and waste)   C$/t mined   8.92   7.60  
Process cost   C$/t milled   42.71   34.18  
G&A   C$/t milled   17.44   13.20  
Transport Cost   C$/t conc   142.14   119.57  
Total OPEX   C$M   7,203   5,943  
LOM C1 Cost Concentrate   C$/t conc   1,076   868  
LOM AISC   C$/t conc   1,152   946  
LOM C1 Cost of Concentrate (post expansion)   C$/t conc   1,071   847  
LOM AISC (post expansion)   C$/t conc   1,146   922  
Total SUSEX   C$M   506   526  
Total initial CAPEX   C$M     366  
Net Cash Flow (pre-tax)   C$M   10,689   11,095  
NPV (8%) (pre-tax)   C$M   3,004   4,529  
NPV Expansion Only (8%) (pre-tax)   C$M     1,525  
IRR Expansion (pre-tax)   %     50.1%  
Payback (pre-tax)   Months     17  
Net Cash Flow (post-tax)   C$M   7,295   7,471  
NPV (8%) (post-tax)   C$M   2,143   3,112  
NPV Expansion Only (8%) (post-tax)   C$M     969  
IRR Expansion (post-tax)   %     41.8%  
Payback (post-tax)   Month     25  
               

Notes:

  • All costs and sales are presented in constant 2026 CAD, with no inflation or escalation factors considered.
  • $M = millions of dollars.
  • The financial analysis was performed on existing Ore Reserves as outlined in this report.
  • The valuation calculations are unlevered.
  • The average metallurgical recovery over the LOM is 71.2% for the expansion and 69.2% for the base case due to improvement in the mill flowsheet specifically attributable to wet high-intensity magnetic separator (WHIMS) improvements.
  • Plant availability is calculated at 90%.
  • Tonnes of concentrate are presented as dry metric tonnes.
  • An exchange rate of 1.35 CAD/USD was fixed over the LOM for the Project.
  • The average 6% Li2O concentrate (SC6) price is based on a market analysis from Benchmark Mineral Intelligence for Q1 2026 as described in the market section and varies over the LOM from US$1,260/t to US$2,430/t.
  • Average LOM SC6 pricing may vary between the cases due to longer mine life at the long term US$2,430 price for the base case (2036 and beyond).
  • A discount rate of 8% was used for the base case and expansion scenarios.
  • Net Cash Flow and valuation calculations include investment tax credit on CAPEX.
  • The numbers have been rounded. Any discrepancy in the totals is due to rounding effects.

There are other costs that have been considered in the Project’s financial analysis, as described in the following sub-sections.


Reconciliation with Previous Scoping Study

The motivation of the revised scoping is to reduce risk in the project execution by staging integration of new infrastructure, bring forward production increase and adjust the throughput versus the last study. Indirectly the price of Spodumene is updated to ensure the pertinence of the study in the reality of the commodity price, the table below compares the previous study expansion scenario to the update in this study.


Table 14 – Expansion Scenarios – Previous Study and Latest Update.

Parameters   Unit   Previous Scoping   Latest Scoping   Variance %  
Exchange Rate   CAD/USD   1.35   1.35    
LOM   Years   24   21   -13%  
Average Price 6% Li2O   USD$/t   1,392   2,154   54.7%  
Mining Cost (ore and waste)   C$/t mined   7.60   7.60    
Process Cost   C$/t milled   35.4   34.2   -3.3%  
G&A   C$/t milled   13.4   13.2   -0.7%  
Transport Cost   C$/t conc   123.8   119.6   -3.5%  
Total OPEX   C$M   6,062   5,943   -2.0%  
LOM C1 Cost Concentrate   C$/t conc   877   868   -1.0%  
LOM AISC   C$/t conc   952   946   -0.6%  
LOM C1 Cost of Concentrate (post expansion)   C$/t conc   851   847   -0.5%  
LOM AISC (post expansion)   C$/t conc   922   922    
Total SUSEX   C$M   517   526   1.7%  
Total Initial CAPEX   C$M   366   366    
Net Cash Flow (pre-tax)   C$M   4,626   11,095   139.4%  
NPV (8%) (pre-tax)   C$M   1,798   4,529   151.9%  
NPV Expansion Only (8%) (pre-tax)   C$M   628   1,525   142.8%  
IRR Expansion (pre-tax)   %   26.4%   50.1%   89.8%  
Payback (pre-tax)   Months   36   17   -52.8%  
Net Cash Flow (post-tax)   C$M   3,249   7,471   130.0%  
NPV (8%) (post-tax)   C$M   1,284   3,112   142.4%  
NPV Expansion Only (8%) (post-tax)   C$M   479   969   102.3%  
IRR Expansion (post-tax)   %   26.4%   41.8%   58.3%  
Payback (post-tax)   Month   46   25   -45.7%  
 

To better understand the impact of staging improvements, the staging, operating cost and throughput increase is separated from the changes in price. The following table shows the contribution of each to the increase in NPV the expansion scenario. As shown in Table 15 below, 51% of the increase in post-tax NPV is attributable to staging/throughput and other assumption changes while 49% is attributable to the increase in Li2O price from the previous study.


Table 15 – Expansion NPV contribution – Staging/Throughput and Price Li



2



O.

Parameters   Unit   Staging /
Throughput*
  Price Li

2

O
  Total NPV increase  
NPV Expansion Only (8%) (pre-tax)   C$M   437   461   898  
NPV Expansion Only (8%) (post-tax)   C$M   251   239   490  
 
*Predominantly staging/throughput in addition to other assumption changes
 

*Predominantly staging/throughput in addition to other assumption changes

Sensitivity Analysis

A sensitivity analysis was conducted on the factors presented below:

  • Spodumene Price
  • Exchange Rate
  • Blended Li2O Grade
  • OPEX
  • Project CAPEX
  • Sustaining CAPEX
  • Mill Recovery

Post-Tax NPV8% sensitivities range from -30% to +30% for all factors. The impact of the NPV (in CAD $M) outputs was tested at discount rate of 8%.

Funding

If the Company proceeds with the expansion, Elevra will consider available funding options including cashflows from existing production, new loan facilities, equity investments, strategic partners, offtake funding or other sources.

Risks and Opportunities


Project Risk Assessment

A risk assessment workshop was performed during the updated scoping study to identify the project risks, determine mitigations measures, and develop a risk register. The key residual risks after mitigation measures have been identified are listed below:

  • Significant increase in ROM pad traffic due to higher throughput requirements
  • Insufficient grinding capacity even with additional ball mill line
  • Degraded flotation performance due to increased throughput
  • Power requirements above current allocation with Hydro-Quebec requiring further permitting
  • Damage to existing plant equipment during construction
  • Damage to new equipment during construction
  • Environmental impact of temporary crushing circuit
  • Difficulties obtaining permit/approval to drain nearby lake (Lake Lortie)
  • Difficulties obtaining social license in the Project footprint
  • Capital escalation

These risks will be tracked through the next project phases. The risk register will be updated as the project progresses. As the mitigations identified will be applied in subsequent phases, the likelihood of such risks will diminish or be removed.


Project Opportunities

There are several opportunities, including the potential for cost reduction opportunities, process recovery enhancements and design improvements. Specific examples of opportunities being investigated in the next phase include ore sorting performance optimisation, ball mill sizing optimisation, modularisation of equipment packages and use of prefabricated concrete. Federal and Provincial government incentives are a potential to reduce the cost of the project either by direct support or tax incentives, this will be pursued further in the subsequent phase of the project.

Announcement authorised for release by Elevra’s Board of Directors.
 

About Elevra Mining

Elevra Lithium Limited is a North American lithium producer (ASX:ELV; NASDAQ:ELVR) with projects in Québec, Canada, United States and Western Australia.

Elevra’s assets comprise North American Lithium (100%), a 60% stake in the Moblan Lithium Project in Central Québec and the Carolina Lithium project (100%) in the United States3.

In Western Australia, the Company holds a large tenement portfolio in the Pilbara region prospective for gold and lithium.

For more information, please visit us at www.elevra.com.


References to Previous ASX Releases

  • Elevra ASX announcement “Accelerated NAL Expansion” dated 12 January 2026
  • Sayona ASX announcement “NAL Expansion Scoping Study Confirms Lower Costs and Strong Returns” dated 15 September 2025
  • Sayona ASX announcement “NAL Resources and Reserves Increases” dated 27 August 2025
  • Sayona ASX announcement “Quarterly Activities Report – June 2025” dated 30 July 2025
  • Sayona ASX announcement “Quarterly Activities Report – March 2025” dated 28 April 2025
  • Sayona ASX announcement “Quarterly Activities Report – December 2024” dated 31 January 2025
  • Sayona ASX announcement “Quarterly Activities Report – September 2024” dated 24 October 2024
  • Sayona ASX announcement “Quarterly Activities/Appendix 5B Cash Flow Report” dated 25 July 2024
  • Sayona ASX announcement “Quarterly Activities/Appendix 5B Cash Flow Report” dated 26 April 2024


Competent Person’s Statement

The information on Mineral Resources and Ore Reserves are extracted from the announcement entitled “NAL Resources and Reserves Increases” published on the ASX on 27th August 2025 and is available to view on the Elevra’s website or on the ASX. The Company confirms that it is not aware of any new information or data that materially affects the information included in the original market announcement and all material assumptions and technical parameters continue to apply and have not materially changed. The Company confirms that the form and context in which the Competent Person’s findings are presented have not been materially modified from the original market announcements

The ASX release dated 27th August 2025 that relates to Mineral Resources for the NAL project – referred to in this announcement – is based on and fairly represents information compiled by Mrs Emilie Gosselin, a member of the Ordre des Ingénieurs du Québec (OIQ). Mrs Gosselin is a full‐time employee of BBA Inc. Mrs Gosselin has sufficient experience which is relevant to the style of mineralisation and type of deposit under consideration and to the activity which she is undertaking to qualify as a Competent Person as defined in the JORC Code (2012 Edition) of the “Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves.” The Company confirms that the form and context in which the Competent Person’s findings are presented have not been materially modified from the original market announcements

The information in this announcement and the ASX release dated 27th August 2025 relating to Ore Reserves for the North American Lithium project is based on, and fairly represents, information and supporting documentation prepared by Mr. Tony O’Connell an independent consultant employed by Optimal Mining Solutions Pty Ltd and is a member of the Australasian Institute of Mining and Metallurgy (AusIMM). Mr O’Connell has sufficient experience which is relevant to the type of deposits and mining method under consideration and to the activity which has been undertaken to qualify as a Competent Person as defined in the 2012 Edition of the “Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves”. The Company confirms that the form and context in which the Competent Person’s findings are presented have not been materially modified from the original market announcements.


Forward Looking Statements

This press release contains certain forward-looking statements. Such statements include, but are not limited to, statements relating to “reserves” or “resources”. Forward-looking statements are based on certain assumptions and involve known and unknown risks, uncertainties and other factors, many of which are beyond Elevra’s control. Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such forward-looking statements.

                          

1 ASX release 15 September 2025 “NAL Expansion Scoping Study”.
2 Converted at CAD/USD = 1.35
3 Average Price 6% Li2O varies between the cases due to longer mine life at the long term US$2,430 price for the base case (2036 and beyond).
4 See ASX release dated 11 May 2026, “Elevra enters agreement to sell Ewoyaa Project Interest”.



For more information, please contact:

Andrew Barber

Investor Relations

Ph: +617 3369 7058

LU Deadline: LU Investors Have Opportunity to Lead Lufax Holding Ltd Securities Fraud Lawsuit First Filed by the Firm

PR Newswire

NEW YORK, May 11, 2026 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lufax Holding Ltd (NYSE: LU) between April 7, 2023 and January 26, 2025, both dates inclusive (the “Class Period”), of the important May 20, 2026 in the securities class action first filed by the Firm.

So What: If you purchased Lufax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Lufax class action, go to https://rosenlegal.com/submit-form/?case_id=53703 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 20, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Lufax lacked adequate internal controls; (2) certain of Lufax’s financial results were materially misstated; and (3) as a result, defendants’ statements about Lufax’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Lufax class action, go to  https://rosenlegal.com/submit-form/?case_id=53703 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY  10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lu-deadline-lu-investors-have-opportunity-to-lead-lufax-holding-ltd-securities-fraud-lawsuit-first-filed-by-the-firm-302768768.html

SOURCE THE ROSEN LAW FIRM, P. A.